14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SGMO vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SGMO carries a Unified Composite Score of 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. ENTX 48.1/100 HOLD), ENTX captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (-100.0% vs. +88.4% YoY).
Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $560.7M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SGMO vs ENTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SGMO carries a Unified Composite Score of 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. ENTX 48.1/100 HOLD), ENTX captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (-100.0% vs. +88.4% YoY). Technical & Structure Timing Caution: SGMO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 50.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SGMO leads the Growth & Scale pillar: SGMO posts +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2022 to Q4 '25), SGMO cumulative revenue shifted +100.0% while ENTX shifted N/A. In operating R&D and SG&A reinvestment, SGMO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
SGMO screens cheaper on headline valuation multiples. SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGMO (-2891.8% ROE) versus ENTX (-138.9% ROE) capital efficiency.
In options market volatility and institutional positioning, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk). By comparison, ENTX carries 164.0% implied volatility (47th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.